Koninklijke Bibliotheek, National Library of the Netherlands
IP1587981042432
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
Canonica, Giorgio Walter
Colombo, Giorgio Lorenzo
Bruno, Giacomo Matteo
Di Matteo, Sergio
Martinotti, Chiara
Blasi, Francesco
Bucca, Caterina
Crimi, Nunzio
Paggiaro, Pierluigi
Pelaia, Girolamo
Passalaqua, Giovanni
Senna, Gianenrico
Heffler, Enrico
text
article
monographic
World allergy organization journal
continuing
19394551
0000000040289
12
1
text
Born digital tijdschriften
KB collectiekavel
text
Elektronische Wetenschappelijke Tijdschriften
EWTIJ
10.1016/j.waojou.2018.12.001
urn:nbn:nl:kb-1587981042176
Automatisch gegenereerd op basis van de EWTIJ XML in release 1.5 van het digitaal magazijn.
WAOJOU
7
100007
S1939-4551(19)30052-3
10.1016/j.waojou.2018.12.001
The Authors
Fig. 1
Annual cost related to oral corticosteroids-related adverse events in target population.
Fig. 1
Fig. 2
Incremental cost scenario: cost related to oral corticosteroids-related adverse events in main analysis.
Fig. 3
Incremental cost scenario: cost related to oral corticosteroids-related adverse events in sub-analysis scenario.
Table 1
Study population: demographic data input.
Table 1
Demographic data
Italian resident population (2017)
60,589,445
Asthma prevalence in Italy
6.60%
SA patients of total asthmatics
5%
SA patients treated with OCS
62%
Table 2
Prevalence rates of potential systemic corticosteroid-induced comorbidity.
Table 2
Comorbidity
Prevalence rates
a
Non-astma controls
Mild/moderate Asthma
Severe Asthma
%
%
%
Type II diabetes
6%
7%
10%
Obesity (BMI >30)
23%
35%
42%
Osteopenia
2%
2%
10%
Osteoporosis
3%
4%
16%
Fracture
4%
3%
5%
Dyspeptic disorders
24%
34%
65%
Glaucoma
3%
3%
4%
Cataract
4%
5%
9%
Cardiovascular disease
7%
7%
10%
Hypertension
25%
29%
34%
Psychiatric disorders
25%
31%
38%
Hypercholesterolaemia
11%
14%
15%
Sleep disorder
2%
3%
4%
Chronic kidney disease
7%
9%
14%
Sweeney J et al. Thorax 2016; 71:339–346.
a
2-year study period.
Table 3
Asthma comorbidities: cost per event.
Table 3
Comorbidity
Event cost
Type II diabetes
€1391.49
Obesity (BMI >30)
€1757.84
Osteopenia
€940.33
Osteoporosis
€1037.82
Fracture
€1984.96
Dyspeptic disorders
€958.51
Glaucoma
€1051.07
Cataract
€1051.07
Cardiovascular disease
€2096.82
Hypertension
€963.36
Psychiatric disorders
€1941.81
Hypercholesterolaemia
€428.43
Sleep disorder
€1408.88
Chronic kidney disease
€3734.46
Table 4
Asthma comorbidities: cost of illness study results.
Table 4
Comorbidity
Cost of Illness (mean annual cost)
Type II diabetes
€ 2792
Obesity
€ 1166
Osteoporosis
€ 1325
Glaucoma
€ 734
Chronic kidney disease
€ 4508
Pagano et al. Nutrition, Metabolism & Cardiovascular Diseases (2016).
Colao A et al. BMJ Open 2017;7:e013899.
Degli Esposti L, et al. Farmeconomia e percorsi terapeutici 2011; 12(3).
Koleva D et al. Ophthalmologica 2007; 221: 340-347.
Turchetti G et al.Eur J Health Econ (2017) 18:847–858.
Table 5
Cost per patient related to comorbidities.
Table 5
Comorbidity
Non-asthma control
Moderate asthma
Severe asthma
Type II diabetes
€ 83,49
€ 97,40
€ 139,15
Obesity (BMI >30)
€ 404,30
€ 615,24
€ 738,29
Osteopenia
€ 18,81
€ 18,81
€ 94,03
Osteoporosis
€ 31,13
€ 41,51
€ 166,05
Fracture
€ 79,40
€ 59,55
€ 99,25
Dyspeptic disorders
€ 230,04
€ 325,89
€ 623,03
Glaucoma
€ 31,53
€ 31,53
€ 42,04
Cataract
€ 42,04
€ 52,55
€ 94,60
Cardiovascular disease
€ 146,78
€ 146,78
€ 209,68
Hypertension
€ 240,84
€ 279,38
€ 327,54
Psychiatric disorders
€ 485,45
€ 601,96
€ 737,89
Hypercholesterolaemia
€ 47,13
€ 59,98
€ 64,26
Sleep disorder
€ 28,18
€ 35,22
€ 56,36
Chronic kidney disease
€ 261,41
€ 336,10
€ 522,83
Total for 2-year analysis
€ 2130.54
€ 2701.91
€ 3915.00
Annual total cost
1065.27 €
1350.96 €
1957.50 €
Table 6
Sensibility analysis results.
Table 6
Main scenario
Annual cost
Incremental cost
Non-asthma control
€ 2131
Severe asthma vs control
€ 1784
Moderate asthma
€ 2702
Severe asthma vs moderate
€ 1213
Severe asthma
€ 3915
Moderate asthma vs control
€ 571
Lombardia DRG cost
Annual cost
Incremental cost
Non-asthma control
€ 2441
Severe asthma vs control
€ 2263
Moderate asthma
€ 3099
Severe asthma vs moderate
€ 1605
Severe asthma
€ 4704
Moderate asthma vs control
€ 658
DRG National tarriffs -20%
Annual cost
Incremental cost
Non-asthma control
€ 1704
Severe asthma vs control
€ 1428
Moderate asthma
€ 2162
Severe asthma vs moderate
€ 970
Severe asthma
€ 3132
Moderate asthma vs control
€ 457
DRG National tarriffs +20%
Annual cost
Incremental cost
Non-asthma control
€ 2557
Severe asthma vs control
€ 2141
Moderate asthma
€ 3242
Severe asthma vs moderate
€ 1456
Severe asthma
€ 4698
Moderate asthma vs control
€ 686
Prevalence rates -20%
Annual cost
Incremental cost
Non-asthma control
€ 1704
Severe asthma vs control
€ 1428
Moderate asthma
€ 2162
Severe asthma vs moderate
€ 970
Severe asthma
€ 3132
Moderate asthma vs control
€ 457
Prevalence rates +20%
Annual cost
Incremental cost
Non-asthma control
€ 2557
Severe asthma vs control
€ 2141
Moderate asthma
€ 3242
Severe asthma vs moderate
€ 1456
Severe asthma
€ 4698
Moderate asthma vs control
€ 686
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
Giorgio Walter
Canonica
a
b
∗
giorgio_walter.canonica@hunimed.eu
Giorgio Lorenzo
Colombo
c
d
giorgio.colombo@savestudi.it
Giacomo Matteo
Bruno
d
giacomo.bruno@savestudi.it
Sergio
Di Matteo
d
sergio.dimatteo@savestudi.it
Chiara
Martinotti
d
chiara.martinotti@savestudi.it
Francesco
Blasi
e
f
francesco.blasi@unimi.it
Caterina
Bucca
g
caterina.bucca@unito.it
Nunzio
Crimi
h
crimi@unict.it
Pierluigi
Paggiaro
i
pierluigi.paggiaro@unipi.it
Girolamo
Pelaia
j
pelaia@unicz.it
Giovanni
Passalaqua
k
passalacqua@unige.it
Gianenrico
Senna
l
gianenrico.senna@aovr.veneto.it
Enrico
Heffler
a
b
enrico.heffler@hunimed.eu
on the behalf of the
SANI Network
m
Stefano
Aliberti
Diego
Bagnasco
Sarah
Barbuto
Gianna
Camiciottoli
Marco
Caminati
Giselda
Colombo
Teresa
Costantino Maria
Claudia
Crimi
Mariangiola
Crivellaro
Mariella
D'Amato
Elisabetta
Favero
Pia
Foschino Maria
Gabriella
Guarnieri
Manuela
Latorre
Carlo
Lombardi
Francesco
Menzella
Vincenzo
Patella
Francesca
Puggioni
Erminia
Ridolo
Giovanni
Rolla
Eleonora
Savi
Nicola
Scichilone
Paolo
Solidoro
Giuseppe
Spadaro
Massimo
Triggiani
a
Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Rozzano, MI, Italy
Personalized Medicine, Asthma and Allergy
Humanitas Research Hospital
Rozzano
MI
Italy
b
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele
MI
Italy
c
Drug Science Department, Pavia University, Italy
Drug Science Department
Pavia University
Italy
d
Studi Analisi Valutazioni Economiche (S.A.V.E.) S.r.l., Health Economics & Outcomes Research Center, Milan, Italy
Studi Analisi Valutazioni Economiche (S.A.V.E.) S.r.l., Health Economics & Outcomes Research Center
Milan
Italy
e
Department of Pathophysiology and Transplantation, University of Milan, Italy
Department of Pathophysiology and Transplantation
University of Milan
Italy
f
Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS “Cà Granda – Ospedale Maggiore Policlinico”, Milan, Italy
Internal Medicine Department
Respiratory Unit and Adult Cystic Fibrosis Center
Fondazione IRCCS “Cà Granda – Ospedale Maggiore Policlinico”
Milan
Italy
g
Pneumology Unit, Cardiovascular and Thoracic Department, AOU Molinette “Città della Salute e della Scienza”, Department of Medical Sciences, University of Torino, Italy
Pneumology Unit
Cardiovascular and Thoracic Department
AOU Molinette “Città della Salute e della Scienza”
Department of Medical Sciences
University of Torino
Italy
h
Allergy and Respiratory Medicine, Department of Clinical and Experimental Medicine, University of Catania, Italy
Allergy and Respiratory Medicine
Department of Clinical and Experimental Medicine
University of Catania
Italy
i
Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Italy
Department of Surgery, Medicine, Molecular Biology and Critical Care
University of Pisa
Italy
j
Department of Medical and Surgical Sciences, Respiratory Unit – University Magna Graecia of Catanzaro, Italy
Department of Medical and Surgical Sciences
Respiratory Unit – University Magna Graecia of Catanzaro
Italy
k
Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI) – University of Genoa, Italy
Allergy and Respiratory Diseases
Department of Internal Medicine (DIMI) – University of Genoa
Italy
l
Asthma Center and Allergy Unit, University of Verona and General Hospital, Verona, Italy
Asthma Center and Allergy Unit
University of Verona and General Hospital
Verona
Italy
∗
Corresponding author. Personalized Medicine, Asthma and Allergy, Humanitas University & Research Hospital, Via Alessandro Manzoni 113, 20089, Rozzano, MI, Italy.
Personalized Medicine, Asthma and Allergy
Humanitas University & Research Hospital
Via Alessandro Manzoni 113
Rozzano
MI
20089
Italy
m
Stefano Aliberti (Milano), Diego Bagnasco (Genova), Sarah Barbuto (Catanzaro), Gianna Camiciottoli (Firenze), Marco Caminati (Verona), Giselda Colombo (Milano), Teresa Costantino Maria (Mantova), Claudia Crimi (Catania), Mariangiola Crivellaro (Padova), Mariella D'Amato (Napoli), Elisabetta Favero (Conegliano Veneto), Pia Foschino Maria (Foggia), Gabriella Guarnieri (Padova), Manuela Latorre (Pisa), Carlo Lombardi (Brescia), Francesco Menzella (Reggio Emilia), Vincenzo Patella (Battipaglia), Francesca Puggioni (Milano), Erminia Ridolo (Parma), Giovanni Rolla (Torino), Eleonora Savi (Piacenza), Nicola Scichilone (Palermo), Paolo Solidoro (Torino), Giuseppe Spadaro (Napoli), Massimo Triggiani (Salerno).
Abstract
Background
Asthma is one of the most common non-communicable respiratory diseases, affecting about 6% of the general population. Severe asthma, even if afflicts a minority of asthmatics, drives the majority of costs of the disease. The aim of this study is to create a pharmacoeconomic model to predict the costs of corticosteroid-related adverse events in severe asthmatics and applying it to the first published epidemiologic data from the Severe Asthma Network in Italy (SANI) registry.
Methods
The analysis was conducted from the perspective of the Italian National Healthcare System (INHS). Model inputs, derived from literature, included: asthma epidemiology data, frequency of adverse events, percentage of severe asthma treated with OCS and adverse event cost (Diagnosis-Related Group (DRG) national tariffs). We estimated costs per different patient groups: non-asthma controls, mild/moderate and severe asthmatics. Final results report estimated direct cost per patient and total direct cost for overall target population, showing economic impact related to corticosteroid complication.
Results
Based on epidemiological data input, in Italy, asthmatic subjects resulted about 3,999,600, of which 199,980 with severe asthma. The number of patients with severe asthma OCS-treated was estimated at 123,988. Compared to the non-asthma control cohort and to that with moderate asthma annual cost per severe asthmatic patient resulted respectively about €892 and €606 higher, showing a corticosteroids shadow cost ranging from 45% to 30%.
Applying the cost per patient to the target population identified for Italy, the budget impact model estimated a total annual cost related to OCS-related adverse events of €242.7 million for severe asthmatics. In respect with non-asthmatic and moderate population, an incremental expenditure of about € 110.6 million and €75.2, respectively, were shown.
Conclusions
Our study provides the first estimates of additional healthcare costs related to corticosteroid induced adverse events in severe asthma patient. Budget impact model results highlighted the relevant economic impact of OCS-related adverse events in severe asthma patients. The future extrapolation of additional data from SANI registry will support the development of a model to investigate the role of corticosteroids sparing drugs.
Keywords
Severe asthma
Oral corticosteroids
Adverse events
Pharmacoeconomy
Costs
Diabetes
Glaucoma
Obesity
Bone fracture
Chronic kidney disease
Introduction
Asthma is one of the most common non-communicable respiratory disease, affecting about 6% of general population, that is currently more than 300 millions of people in the world
1,2
; the trend of asthma prevalence seems to be at least stable,
1
if not even increasing in the last few years.
2,3
This epidemiological situation accounts for high and increasing health-related costs (direct and indirect),
4–9
particularly in those patients with suboptimal control of asthma.
10,11
Most of the patients with asthma achieve a good control of the disease using regularly low-to-medium doses of inhaled corticosteroids±other controllers, but a small proportion (accounting about 3.5–10% of all asthmatics
12–15
) requires high dose of these drugs (and/or systemic corticosteroids) to be controlled or remains uncontrolled despite this therapy: these patients are defined as “severe asthmatics” according to the latest European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines.
16
Severe asthma, although afflicting a minority of these patients, drives most costs of the disease.
17
Moreover, it is precisely the patients with more severe asthma (particularly if they have associated comorbidities and high peripheral eosinophils levels) who use systemic corticosteroids more frequently and at high dosages, with an increased risk of corticosteroid-related adverse events.
18–20
Indeed, it is known that systemic corticosteroids are not without side effects, and that these are more frequent and severe in patients who use them continuously or frequently.
21,22
The major adverse events related to the use of systemic corticosteroids (that are common to patients using high doses of inhaled corticosteroids for prolonged time
23
) are: hypertension, osteoporosis and bone fracture, cataract and glaucoma, diabetes, respiratory infections, reduced growth velocity in children, and hypothalamic-pituitary-adrenal axis suppression.
Few studies analysed the impact, in terms of costs, of corticosteroid-related adverse events in several diseases, including asthma
19,20,22,24–27
: the estimated annual cost in asthmatics ranges from about 600 Euros
26
to about 5000 Euros in more severe patients.
27
The aim of this study is to create a pharmacoeconomic model to predict the costs of corticosteroid-related adverse events in severe asthmatics and applying it to the first published epidemiologic data from the Severe Asthma Network in Italy (SANI) registry.
28,29
Materials and methods
Study design
A budget impact model (BIM) was developed to evaluate the pharmacoeconomic consequences of oral corticosteroid adverse events (OCS-AE) in adult patients with severe asthma. The analysis was conducted through a dynamic simulation model in Microsoft Excel® and carried out from the perspective of the Italian National Healthcare System (INHS). Our study initially provided a literature review aimed to identify data on:
•
asthma epidemiology
•
asthmatic comorbidities related to corticosteroids use
•
frequency of adverse events in severe asthma patients
•
adverse events cost
Model inputs included asthma epidemiology data, frequency of adverse events, percentage of severe asthma patients treated with OCS and adverse events cost. After identifying the study population and main OCS-related adverse events in adult's asthma patients, the economic impact of adverse events was estimated based on adverse events rate and events cost. Economic evaluation was conducted considering a main scenario, including all adverse events considered in a Sweeney's et al study that investigated the prevalence of systemic corticosteroid-induced morbidity in severe asthma using data from Optimum Patient Care Research Database (OPCRD) and British Thoracic Society (BTS) Difficult Asthma Registry.
19
Specifically, we adopted prevalence data obtained from OPCRD database that included 7195 subjects in three age and gender matched groups: severe asthma (808), mild/moderate asthma (3975) and non-asthma controls (2412): patients with SA requiring regular OCS (GINA step 5) were compared with patients with mild/moderate asthma and non-asthmatic controls.
Adverse events evaluation was developed adopting Diagnosis-Related Group (DRG)-based national tariffs (diagnosis-related group tariffs system). In addition, an analysis subgroup, including some of most common OCS-related adverse events reported in available studies was considered: we researched cost of illness studies available in literature for Italy for diseases in analysis in order to use an alternative evaluation method, not related only to the acute event as it happens with the DRG system, and to observe their impact on the total. Based on different prevalence rates of morbidities associated with systemic steroid exposure provided by literature,
19
we estimated costs per different patient groups: non-asthma controls, mild/moderate and severe asthmatics. Combining epidemiology data with frequency and OCS-related adverse events cost, we obtained budget impact analysis results. Final results report estimated direct cost per patient and total direct cost for overall target population, showing economic impact related to corticosteroid complications, potentially avoidable if these drugs were no longer administered.
Lastly, in order to assess the robustness of results, a deterministic sensibility analysis was developed changing main parameters used for the calculation (cost of adverse events and prevalence rates of OCS-related adverse events) by ±20%. In addition, for event costs we considered DRG costs related to Lombardy Region, as an alternative to national tariffs given the variability on the territory.
Study population
In order to obtain the target population, we started from national epidemiological data derived from Italian National Statistical Institute (ISTAT).
30
As shown in Table 1
, a 6.6% of asthma prevalence was applied to the total resident population in Italy, and 5% of asthmatics were considered to be affected by severe asthma (based on literature and expert opinion).
3,28
Finally, it was considered that 62% of patients with severe asthma were chronically treated with OCS, as emerged from the first extractions from SANI database (Severe Asthma Network in Italy).
29
Adverse events rate
Rates of OCS-related adverse events were provided from an observational study published by Sweeney et al., Table 2
. The study was based on Optimum Patient Care Research Database (UK setting) and compared patients with SA requiring regular OCS with patients with mild/moderate asthma and non-asthmatic controls (rhinitis diagnosis with no asthma diagnosis/asthma drugs and no exposure to OCS). The aim of Sweeney's study was to determine the prevalence of systemic corticosteroid-induced morbidity in severe asthma over 2-year analysis. Subjects (7195) had at least 2 years of continuous medical records and were aged >12 years.
Adverse events cost
Economic evaluation of OCS-related adverse events was conducted by DRG Tariffs System, Table 3
. This system classifies all patients in homogeneous groups according to resources absorption, allowing to economically quantify the use of resources and to provide an estimate of the cost per acute event from the INHS perspective.
Moreover, in order to extrapolate data cost from literature, we adopted results from cost of illness studies available for Italy to implement model subgroup analysis. We considered cost of the following illness: type 2 diabetes mellitus (T2DM), obesity, osteoporosis, glaucoma and chronic kidney disease, Table 4
.
31–35
Results
Based on epidemiological data input, in Italy asthmatic subjects turned out to be about 3,999,600, of whom 199,980 with severe asthma. The number of patients with severe asthma OCS-treated was estimated to be 123,988 which represents the proportion of subjects potentially at risk of developing morbidities associated with systemic steroid exposure.
The cost of OCS-related adverse events in the main scenario was derived by combining the cost of each event with the relative rate. Annual costs per patient related to OCS-related adverse events in non-asthma control, mild/moderate, and severe asthma groups resulted equal to €1065,27, €1350,96 and €1957,50 respectively, Table 4.
Compared to the non-asthma control cohort, the annual per patient cost related to OCS-related adverse events resulted about €892 and €285 higher in severe asthma and moderate/mild cohort respectively. Annual per patient cost difference between asthmatic groups was about €606 (see Table 5
).
We extended the total annual cost for patient to the estimated severe asthma Italian population in treatment with OCS (n = 123,988) in order to obtain budget impact results: (Fig. 1
).
Comparing severe asthma annual costs with those of non-asthmatic population, an incremental expenditure of about € 110.6 million was shown, which was reduced to about € 75.2 compared to the moderate asthma. The difference between the population with moderate asthma compared to the non-asthmatic control was lower, reaching approximately €35.4 million (Fig. 2
).
Subgroup analysis
We evaluated the economic impact of the five most common OCS-adverse event, considering cost of illness studies available, in order to adopt an alternative method to DRG tariffs. The results are shown in Fig. 3
. Specifically, the subgroup analysis allowed to highlight the economic impact exercised by type 2 diabetes, obesity, fractures, glaucoma and chronic kidney disease according to literature data. These five diseases alone were able to result in a total annual cost equal to €92.7 million in the population with severe asthma, involving an additional expenditure of approximately €41.5 million compared to control and €26.3 million compared to populations with moderate asthma (Fig. 3).
Sensibility analysis
In Table 6
sensibility analysis results are shown.
Using a deterministic sensitivity analysis (DSA), we investigated the sensitivity of the results from the model-based analysis to variations in cost of adverse events and prevalence rates of OCS-related adverse events, which are among the main input parameters used for the cost analysis. Specifically, varying these values by ±20%, no significant changes in the final results were reported, highlighting the robustness of the budget impact analysis result.
Discussion
This budget impact analysis highlighted the significant economic burden of morbidity related to systemic corticosteroid exposure in severe asthma population from the Italian NHS perspective. Our analysis, starting from national demographic data, asthma epidemiological data and adopting first published extractions from the Severe Asthma Network in Italy (SANI) registry, identified the proportion of subjects potentially at risk of developing comorbidities associated with systemic steroid exposure and showed that co-morbid costs were greater in the severe asthma patients, subjected to treatment with high-medium oral corticosteroids, compared to moderate and non-asthmatic cohort.
Total annual cost per patient associated with comorbid conditions due to OCS use was estimated at €1957.50 for the severe asthma cohort, almost twice that non-asthmatic population, and more than 30% compared to the population with moderate asthma, (€1350.96). Annual cost per patient difference between severe and moderate groups was about €606. The cost was determined by the higher prevalence of OCS-related adverse events in severe asthma cohort, considering the correlation between regular intensive use of systemic steroid therapy and disease onset and consequent impact on cost. For the analysis we considered the co-morbidities most frequently associated with the use of corticosteroids taken from the Sweeney's study,
19
which provided events prevalence data for the three cohorts in analysis.
Applying the cost per patient to the target population identified for Italy, the budget impact model estimated a total annual cost related to OCS-related adverse events of €242.7 million for severe asthmatics. In respect with non-asthmatic and moderate asthma population, an incremental expenditure of about € 110.6 million and €75.2, respectively, was shown. The micro-costing analysis conducted based on cost of illness studies available for Italy, allowed to evaluate the impact of a subset of diseases, offering an alternative economic evaluation method. Five OCS-related adverse events alone, type 2 diabetes, obesity, fractures, glaucoma and chronic kidney disease, resulted in a total annual cost equal to €92.7 million in the population with severe asthma. The robustness of main analysis was confirmed by sensitivity analysis. Moreover, given regional tariffs variability in Italy for acute care hospital services, in order to provide an example of regional valorisation, we adopted DRG tariffs used in Lombardy region, recognized higher than the national average.
According to international guidelines, oral corticosteroid (OCS) treatment in asthma should be reserved to acute exacerbations (with short course of therapy) or to those severe patients remaining clinically uncontrolled or at high risk for future loss of control, despite high dose of inhaled corticosteroids (ICS) plus another controller, such as long-term beta2-agonists (better if combined, in a single inhaler, with ICS), leukotriene-receptor antagonists (LTRA), tiotropium or theophylline.
36
Anyway, even in case of severe asthma, the suggestion is to use low-dose of OCS as a second-choice treatment after having considered the possibility to use biologic agents such as anti-IgE or anti-IL5 monoclonal antibodies.
36
However, the first published real-life data raised by the SANI registry
29
put in evidence a dramatic situation in which more than 60% of severe asthmatics are chronically taking OCS, being therefore at high risk of OCS-related adverse events. An even more dramatic picture emerged from the updated SANI registry data recently published and showing a prevalence of OCS users higher than 64% of all severe asthmatics.
37
A similar picture has been described by Zeiger et al. in a recent retrospective observational cohort study of adults with persistent asthma: they found an overall prevalence of OCS-treated patients of about 8.2% which corresponded to the great majority of those with severe asthma stigmata.
18
Putting these real-life data together with the evidence that severe asthmatics are often affected by comorbidities requiring chronic use of topical (i.e.: intranasal) or systemic corticosteroids,
19
it is easily predictable that these patients have a high probability to develop corticosteroid adverse events. This risk is further increased considering that also chronic use of high (often higher than suggested) dose of ICS has been associated with significant adverse events.
23,38
The high prevalence of OCS use and the well-known impact of these drugs on the onset of complications, from minor events to potentially life-threating conditions, in any case impacting patient's quality of life, have led to develop studies aimed at considering even their economic impact. Behind the low acquisition cost of these drugs, the cost associated with OCS-induced morbidity hides, representing a shadow cost not to be missed. The significance of this topic, also considering current OCS-sparing effect therapies availability, is demonstrated by various published studies that, in line with ours, paid attention to the economic burden of adverse events associated with drugs exposure.
Some reviews analysed the corticosteroids effect in term of adverse events and cost considering the effects on more pathologies or focusing on the asthma only.
25,39
Findings from these studies showed systemic corticosteroids are a common cause of comorbidities and the costs of managing these events can be substantial. Therefore, clinical and economic burden of systemic related adverse events highlights the need for OCS sparing therapies to be adopted.
Focusing on asthma, some studies have been carried out to evaluate the risk of systemic corticosteroids complications by steroid exposure and quantify the associated health care costs and resource use in patients with severe asthma requiring a regular therapy.
Lefebvre et al. performed a longitudinal, open-cohort, observational study using health insurance claims data; the adjusted risk of systemic corticosteroids related complications for patients with medium and high exposure compared with patients with low exposure and quantify the resulting health care resource use and costs were estimated: patients with medium and high systemic corticosteroids exposure had significantly higher risks of steroids related complications versus those with low exposure.
40
Luskin et al with their cross-sectional, matched-cohort, retrospective study, using a commercial claims database, estimated the prevalence of possible oral corticosteroid (OCS)-related side effects and health care resource use and costs in patients with asthma.
41
Adults with asthma diagnosis codes and evidence of asthma medication use were studied. Patients with high OCS use (≥30 days of OCS annually) with possible OCS-related adverse events were more likely to have office visits and hospitalizations than those without possible side effects. High OCS users with possible side effects had higher adjusted total annual mean health care costs ($25,168) than those without such side effects ($21,882).
41
Our study is consistent with the data reported in literature, highlighting the correlation between the severity of asthmatic disease, and the increase in costs related to systemic corticosteroid-induced morbidities: differences in costs were significant between patients with asthma differentiated by steroid exposure. Moreover, this article is the first data from Italian Registry of Severe Asthma (SANI) that shows economic impact of OCS-overuse. This result is in line with that emerged from Barry's et al study,
27
that have prevalence rates of corticosteroid-induced morbidity in common with our, corresponding to the economic evaluation of the results from the Sweeney study.
19
According to UK NHS, Barry's study aimed to estimate the additional healthcare costs associated with steroid induced morbidity by comparing three patients' groups: those with severe asthma, moderate asthma and no asthma. Average healthcare costs per person per year range from £2603 - £4533 for the severe asthma cohort, to £978 - £2072 for the mild/moderate asthma cohort, to £560 - £1324 for the non-asthma control cohort, depending on different costing scenario considered.
27
The excess risk of complications associated with long-term maintenance OCS use and related cost was also estimated by Tilden et al for the Australian population;
26
this study, in addiction, considered quality-adjusted life year (QALY) losses due to corticosteroids exposure, focusing on eight disease outcomes significantly impacting costs QALY burden: type II diabetes, myocardial infarction, glaucoma, cataract, ulcer, osteoporosis, infection, and stroke. Expected annual cost of maintenance OCS-related disease outcomes resulted $598.32 per patient per year. Each patient treated with maintenance OCS also reported a QALY loss of 0.0367 per year of treatment. These effects are considered reversible once patients stop taking maintenance OCS.
26
Different strategies have been developed to reduce the use of the corticosteroid load in asthma,
42
ranging from allergy immunotherapy (not suitable for uncontrolled asthmatics),
43
to biologic agents used in severe patients, as omalizumab,
44
mepolizumab,
45
benralizumab
46
and dupilumab.
47
The biologic treatment of severe asthma, into the context of a more personalized approach to the patients,
48
seems to be a safe and effective steroid-sparing therapy; biologic agents are generally quite expensive and this, with payer policies, is currently one of the main limitation of their use in clinical practice, even if real-life studies demonstrated that their correct use is globally cost-effectiveness.
49–51
To this purpose, the big data coming from registries like SANI will provide the opportunity to monitor OCS sparing effect of biologic agents in a real-life setting. However, even considering the more long-lived biologic agent for severe asthma (omalizumab), there is the real-life evidence that still a large group of individuals who may benefit from this drug are not receiving it.
52
In the very selected population of patients followed by tertiary reference centers for severe asthma in Italy, composed in 95% of cases of patients classified as GINA V step severity, the underuse of biologic agents is confirmed: only about 60% of those eligible to at least one biologic agent are receiving this kind of therapy.
29
Further studies are needed to investigate if a wider use biologic agent in severe asthmatics may be cost-effective also in terms of reduction of OCS-related adverse events costs.
Our study provides estimates of additional healthcare costs related to corticosteroid induced adverse events in severe asthma patients from the Italian NHS perspective, not analysed previously. Budget impact model results highlighted the relevant economic impact of OCS-related adverse events in severe asthma patients, subjected to regular exposure to corticosteroids, compared to not exposed. The availability of the first epidemiologic data from SANI registry allowed the definition of target population based on national real word data. The future extrapolation of additional data from SANI registry will support the development of a model populated with national data, providing an important tool for further analyses and greater robustness. Indeed, use of adverse events prevalence rates derived from a UK respiratory database (OPCRD)
19
could be seen as a limit of our study. However, it was necessary, because there were no data available for Italy. To overcome the uncertainty of this data, together with that associated with the cost of adverse events, we conducted a sensitivity analysis. Economic evaluation was carried out adopting direct cost associated with corticosteroids related adverse events management, according to Italian NHS. Indirect costs were not considered despite their impact could be relevant due to effects of OCS-related adverse events on productivity and quality of life loss. Overall, the analysis conducted can be considered conservative, indeed the number of evaluable adverse events can be expanded and for economic evaluation we considered unique national tariffs, to achieve greater homogeneity, in a context of national variability.
Declarations
Ethics approval
The study has been approved by the Central Ethics Committee for the SANI Network (Comitato Etico Area Vasta Nord-Ovest Toscana; protocol number: study number 1245/2016, protocol number: 73714).
Consent for publication
Not applicable.
Availability of data
The data that support the findings of this study are available from the Severe Asthma Network in Italy (SANI) but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of SANI.
Competing interests
The authors declare that they have no competing interests.
Authors contribution
GWC, GLC, GMB, SDM, CM, FB, PP and EH: contributed in study conception, study design, literature review, data analysis, data interpretation, writing the manuscript and critical revision of the final draft. GLC,GMB, SDM and CM also created the pharmacoeconomic model here presented.
CB, NC, GPe, GPa and GS contributed in critical revision of the study concept and design, data interpretation, writing the manuscript and critical revion of the final draft.
The SANI Network members contributed in collecting data for the SANI registry and in critical revision of the final draft.
All the Authors read the final version of the manuscript and approved it.
Funding
The SANI Project was supported by GINA Italy/Federasma/SIAAIC/SIP-IRS through Unrestricted support from: AstraZeneca, Italy; Glaxo-Smith & Kline, Italy; Novartis, Italy; Sanofi, Italy; Teva, Italy.
Acknowledgements
We sincerely thank Dr. Concetta Sirena (SANI Project Manager).
List of abbreviations
ATS
American Thoracic Society
BIM
Budget Impact Model
BTS
British Thoracic Society
DRG
Diagnosis-Related Group
ERS
European Respiratory Society
ICS
Inhaled Corticosteroids
INHS
Italian National Healthcare System
ISTAT
Italian National Statistical Institute
LTRA
Leukotriene-Receptor Antagonists
OCS
Oral Corticosteroids
OCS-AE
Oral Corticosteroid Adverse Events
OPCRD
Optimum Patient Care Research Database
QALY
Quality-Adjusted Life Year
SANI
Severe Asthma Network in Italy
T2DM
Type 2 Diabetes Mellitus
References
1
Institute for Health Metrics and Evaluation (IHME)
Global Burden of Diseases (GBD) Studies
http://www.healthdata.org/gbd
2
P.A.
Loftus
S.K.
Wise
Epidemiology and economic burden of asthma
Int Forum Allergy Rhinol
5
Suppl 1
2015
S7
S10
3
R.
de Marco
V.
Cappa
S.
Accordini
GEIRD Study Group
Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010
Eur Respir J
39
4
2012
883
892
4
E.
Costa
R.
Caetano
G.L.
Werneck
M.
Bregman
D.V.
Araújo
R.
Rufino
Estimated cost of asthma in outpatient treatment: a real-world study
Rev Saude Publica
52
2018 Apr 9
27
5
J.M.
Chapel
M.D.
Ritchey
D.
Zhang
G.
Wang
Prevalence and medical costs of chronic diseases among adult medicaid beneficiaries
Am J Prev Med
53
6S2
2017 Dec
S143
S154
6
R.W.
Dal Negro
C.
Distante
L.
Bonadiman
P.
Turco
S.
Iannazzo
Cost of persistent asthma in Italy
Multidiscip Respir Med
11
2016
44
7
S.
Accordini
A.G.
Corsico
M.
Braggion
The cost of persistent asthma in Europe: an international population-based study in adults
Int Arch Allergy Immunol
160
1
2013
93
101
8
T.
Nurmagambetov
R.
Kuwahara
P.
Garbe
The economic burden of asthma in the United States, 2008-2013
Ann Am Thorac Soc
15
3
2018
348
356
9
M.
Fletcher
A.
Jha
W.
Dunlop
Patient reported burden of asthma on resource use and productivity across 11 countries in Europe
Adv Ther
32
4
2015
370
380
10
Z.
Zafari
M.
Sadatsafavi
W.
Chen
J.M.
FitzGerald
The projected economic and health burden of sub-optimal asthma control in Canada
Respir Med
138
2018
7
12
11
F.
Braido
G.
Brusselle
D.
Guastalla
LIAISON Study Group
Determinants and impact of suboptimal asthma control in Europe: the International Cross-Sectional and Longitudinal Assessment on Asthma Control (LIAISON) study
Respir Res
17
1
2016
51
12
D.M.
Lang
Severe asthma: epidemiology, burden of illness, and heterogeneity
Allergy Asthma Proc
36
6
2015
418
424
13
P.P.
Hekking
R.R.
Wener
M.
Amelink
A.H.
Zwinderman
M.L.
Bouvy
E.H.
Bel
The prevalence of severe refractory asthma
J Allergy Clin Immunol
135
4
2015
896
902
14
K.
Larsson
B.
Ställberg
K.
Lisspers
Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR)
Respir Res
19
1
2018
12
15
A.
von Bülow
M.
Kriegbaum
V.
Backer
C.
Porsbjerg
The prevalence of severe asthma and low asthma control among Danish adults
Allergy Clin Immunol Pract
2
6
2014
759
767
16
K.F.
Chung
S.E.
Wenzel
J.L.
Brozek
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Eur Respir J
43
2
2014
343
373
17
L.
Antonicelli
C.
Bucca
M.
Neri
Asthma severity and medical resource utilisation
Eur Respir J
23
5
2004
723
729
18
R.S.
Zeiger
M.
Schatz
Q.
Li
W.
Chen
D.B.
Khatry
T.N.
Tran
Burden of chronic oral corticosteroid use by adults with persistent asthma
J Allergy Clin Immunol Pract
5
4
2017
1050
1060
19
J.
Sweeney
C.C.
Patterson
A.
Menzies-Gow
British Thoracic Society Difficult Asthma Network
Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry
Thorax
71
4
2016
339
346
20
P.
Lefebvre
M.S.
Duh
M.H.
Lafeuille
Burden of systemic glucocorticoid-related complications in severe asthma
Curr Med Res Opin
33
1
2017
57
65
21
D.M.
Poetker
D.D.
Reh
A comprehensive review of the adverse effects of systemic corticosteroids
Otolaryngol Clin
43
4
2010
753
768
22
J.B.
Rice
A.G.
White
L.M.
Scarpati
G.
Wan
W.W.
Nelson
Long-term systemic corticosteroid exposure: a systematic literature review
Clin Therapeut
39
11
2017
2216
2229
23
E.
Heffler
L.N.G.
Madeira
M.
Ferrando
Inhaled corticosteroids safety and adverse effects in patients with asthma
J Allergy Clin Immunol Pract
6
3
2018
776
781
24
M.
Pisu
N.
James
S.
Sampsel
K.G.
Saag
The cost of glucocorticoid-associated adverse events in rheumatoid arthritis
Rheumatology (Oxford)
44
6
2005
781
788
25
S.C.
Manson
R.E.
Brown
A.
Cerulli
C.F.
Vidaurre
The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use
Respir Med
103
7
2009
975
994
26
D.
Tilden
K.
Makino
S.
Cottrell
M.
Needham
Quantifying the cost and quality of life implications of adverse events associated with long-term oral corticosteroid use
Value Health
18
7
2015
A688
27
L.E.
Barry
J.
Sweeney
C.
O'Neill
D.
Price
L.G.
Heaney
The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis
Respir Res
18
1
2017
129
28
G.
Senna
M.
Guerriero
P.L.
Paggiaro
SANI
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
Clin Mol Allergy
15
2017
9
29
M.
Ferrando
E.
Heffler
C.
Sirena
Severe Asthma Network Italy (SANI): first results from a national severe asthma registry
European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018, Munich
26–30 May 2018
Abstract n. 376
30
Geodemo Istat
Tavola Popolazione Totale Italia. [Geodemo Istat Table Total Population Italy]
http://demo.istat.it/pop2017/index.html
31
E.
Pagano
M.
De Rosa
E.
Rossi
The relative burden of diabetes complications on healthcare costs: the population-based CINECA-SID ARNO Diabetes Observatory
Nutr Metabol Cardiovasc Dis
26
10
2016
944
950
32
A.
Colao
M.
Lucchese
M.
D'Adamo
Healthcare usage and economic impact of non-treated obesity in Italy: findings from a retrospective administrative and clinical database analysis
BMJ Open
7
2
2017
e013899
33
L.
Degli Esposti
S.
Adami
G.
Iolascon
Il costo delle fratture da osteoporosi in Italia. Risultati dello studio BLO CK (Bone Loss and Osteoporosis: cost-of-illness Knowledge)
Farmecon Percorsi Ter
12
3
2011
34
D.
Koleva
N.
Motterlini
M.
Schiavone
L.
Garattini
Study Group GLAUCO
Ophthalmologica
221
5
2007
340
347
35
G.
Turchetti
S.
Bellelli
M.
Amato
On Behalf of the Tuscany CKD Study Group
The social cost of chronic kidney disease in Italy
Eur J Health Econ
18
7
2017
847
858
36
Global Initiative for Asthma, https://ginasthma.org. (Accessed 19 July 2018).
37
E.
Heffler
F.
Blasi
M.
Latorre
SANI Network
The severe asthma Network in Italy (SANI): findings and perspectives
J Allergy Clin Immunol Pract
2018
10.1016/j.jaip.2018.10.016
38
I.
Ruggeri
D.
Bragato
G.L.
Colombo
E.
Valla
S.
Di Matteo
Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy
Clinicoecon Outcomes Res
4
2012
375
382
39
E.
Sarnes
L.
Crofford
M.
Watson
G.
Dennis
H.
Kan
D.
Bass
Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review
Clin Therapeut
33
10
2011
1413
1432
40
P.
Lefebvre
M.S.
Duh
M.H.
Lafeuille
Acute and chronic systemic corticosteroid-related complications in patients with severe asthma
J Allergy Clin Immunol
136
6
2015
1488
1495
41
A.T.
Luskin
E.N.
Antonova
M.S.
Broder
E.Y.
Chang
T.A.
Omachi
D.K.
Ledford
Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis
Clinicoecon Outcomes Res
8
2016
641
648
42
E.
Heffler
D.
Bagnasco
G.W.
Canonica
Strategies to reduce corticosteroid-related adverse events in asthma
Curr Opin Allergy Clin Immunol
2018
10.1097/ACI.0000000000000493
43
H.
Mosbech
R.
Deckelmann
F.
de Blay
Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial
J Allergy Clin Immunol
134
3
2014
568
575
44
M.
Bhutani
W.H.
Yang
J.
Hébert
F.
de Takacsy
J.L.
Stril
The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study
PLoS One
12
8
2017
e0183869
45
E.H.
Bel
S.E.
Wenzel
P.J.
Thompson
SIRIUS Investigators
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma
N Engl J Med
371
13
2014
1189
1197
46
P.
Nair
S.
Wenzel
K.F.
Rabe
ZONDA Trial Investigators
Oral glucocorticoid-sparing effect of benralizumab in severe asthma
N Engl J Med
376
25
2017
2448
2458
47
K.F.
Rabe
P.
Nair
G.
Brusselle
Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma
N Engl J Med
378
26
2018
2475
2485
48
G.W.
Canonica
M.
Ferrando
I.
Baiardini
Asthma: personalized and precision medicine
Curr Opin Allergy Clin Immunol
18
1
2018
51
58
49
R.W.
Dal Negro
L.
Pradelli
S.
Tognella
C.
Micheletto
S.
Iannazzo
Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy
Eur Ann Allergy Clin Immunol
43
2
2011
45
53
50
S.D.
Sullivan
F.
Turk
An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma
Allergy
63
6
2008
670
684
51
R.B.
McQueen
D.N.
Sheehan
M.D.
Whittington
J.F.M.
van Boven
J.D.
Campbell
Cost-Effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations
Pharmacoeconomics
2018
10.1007/s40273-018-0658-x
52
M.M.
Jeffery
N.D.
Shah
P.
Karaca-Mandic
J.S.
Ross
M.A.
Rank
Trends in omalizumab utilization for asthma: evidence of suboptimal patient selection
J Allergy Clin Immunol Pract
2017
10.1016/j.jaip.2017.07.034
WAOJOU
7
100007
S1939-4551(19)30052-3
10.1016/j.waojou.2018.12.001
The Authors
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
Giorgio Walter
Canonica
a
b
∗
giorgio_walter.canonica@hunimed.eu
Giorgio Lorenzo
Colombo
c
d
giorgio.colombo@savestudi.it
Giacomo Matteo
Bruno
d
giacomo.bruno@savestudi.it
Sergio
Di Matteo
d
sergio.dimatteo@savestudi.it
Chiara
Martinotti
d
chiara.martinotti@savestudi.it
Francesco
Blasi
e
f
francesco.blasi@unimi.it
Caterina
Bucca
g
caterina.bucca@unito.it
Nunzio
Crimi
h
crimi@unict.it
Pierluigi
Paggiaro
i
pierluigi.paggiaro@unipi.it
Girolamo
Pelaia
j
pelaia@unicz.it
Giovanni
Passalaqua
k
passalacqua@unige.it
Gianenrico
Senna
l
gianenrico.senna@aovr.veneto.it
Enrico
Heffler
a
b
enrico.heffler@hunimed.eu
on the behalf of the
SANI Network
m
Stefano
Aliberti
Diego
Bagnasco
Sarah
Barbuto
Gianna
Camiciottoli
Marco
Caminati
Giselda
Colombo
Teresa
Costantino Maria
Claudia
Crimi
Mariangiola
Crivellaro
Mariella
D'Amato
Elisabetta
Favero
Pia
Foschino Maria
Gabriella
Guarnieri
Manuela
Latorre
Carlo
Lombardi
Francesco
Menzella
Vincenzo
Patella
Francesca
Puggioni
Erminia
Ridolo
Giovanni
Rolla
Eleonora
Savi
Nicola
Scichilone
Paolo
Solidoro
Giuseppe
Spadaro
Massimo
Triggiani
a
Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Rozzano, MI, Italy
Personalized Medicine, Asthma and Allergy
Humanitas Research Hospital
Rozzano
MI
Italy
b
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele
MI
Italy
c
Drug Science Department, Pavia University, Italy
Drug Science Department
Pavia University
Italy
d
Studi Analisi Valutazioni Economiche (S.A.V.E.) S.r.l., Health Economics & Outcomes Research Center, Milan, Italy
Studi Analisi Valutazioni Economiche (S.A.V.E.) S.r.l., Health Economics & Outcomes Research Center
Milan
Italy
e
Department of Pathophysiology and Transplantation, University of Milan, Italy
Department of Pathophysiology and Transplantation
University of Milan
Italy
f
Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS “Cà Granda – Ospedale Maggiore Policlinico”, Milan, Italy
Internal Medicine Department
Respiratory Unit and Adult Cystic Fibrosis Center
Fondazione IRCCS “Cà Granda – Ospedale Maggiore Policlinico”
Milan
Italy
g
Pneumology Unit, Cardiovascular and Thoracic Department, AOU Molinette “Città della Salute e della Scienza”, Department of Medical Sciences, University of Torino, Italy
Pneumology Unit
Cardiovascular and Thoracic Department
AOU Molinette “Città della Salute e della Scienza”
Department of Medical Sciences
University of Torino
Italy
h
Allergy and Respiratory Medicine, Department of Clinical and Experimental Medicine, University of Catania, Italy
Allergy and Respiratory Medicine
Department of Clinical and Experimental Medicine
University of Catania
Italy
i
Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Italy
Department of Surgery, Medicine, Molecular Biology and Critical Care
University of Pisa
Italy
j
Department of Medical and Surgical Sciences, Respiratory Unit – University Magna Graecia of Catanzaro, Italy
Department of Medical and Surgical Sciences
Respiratory Unit – University Magna Graecia of Catanzaro
Italy
k
Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI) – University of Genoa, Italy
Allergy and Respiratory Diseases
Department of Internal Medicine (DIMI) – University of Genoa
Italy
l
Asthma Center and Allergy Unit, University of Verona and General Hospital, Verona, Italy
Asthma Center and Allergy Unit
University of Verona and General Hospital
Verona
Italy
∗
Corresponding author. Personalized Medicine, Asthma and Allergy, Humanitas University & Research Hospital, Via Alessandro Manzoni 113, 20089, Rozzano, MI, Italy.
Personalized Medicine, Asthma and Allergy
Humanitas University & Research Hospital
Via Alessandro Manzoni 113
Rozzano
MI
20089
Italy
m
Stefano Aliberti (Milano), Diego Bagnasco (Genova), Sarah Barbuto (Catanzaro), Gianna Camiciottoli (Firenze), Marco Caminati (Verona), Giselda Colombo (Milano), Teresa Costantino Maria (Mantova), Claudia Crimi (Catania), Mariangiola Crivellaro (Padova), Mariella D'Amato (Napoli), Elisabetta Favero (Conegliano Veneto), Pia Foschino Maria (Foggia), Gabriella Guarnieri (Padova), Manuela Latorre (Pisa), Carlo Lombardi (Brescia), Francesco Menzella (Reggio Emilia), Vincenzo Patella (Battipaglia), Francesca Puggioni (Milano), Erminia Ridolo (Parma), Giovanni Rolla (Torino), Eleonora Savi (Piacenza), Nicola Scichilone (Palermo), Paolo Solidoro (Torino), Giuseppe Spadaro (Napoli), Massimo Triggiani (Salerno).
Abstract
Background
Asthma is one of the most common non-communicable respiratory diseases, affecting about 6% of the general population. Severe asthma, even if afflicts a minority of asthmatics, drives the majority of costs of the disease. The aim of this study is to create a pharmacoeconomic model to predict the costs of corticosteroid-related adverse events in severe asthmatics and applying it to the first published epidemiologic data from the Severe Asthma Network in Italy (SANI) registry.
Methods
The analysis was conducted from the perspective of the Italian National Healthcare System (INHS). Model inputs, derived from literature, included: asthma epidemiology data, frequency of adverse events, percentage of severe asthma treated with OCS and adverse event cost (Diagnosis-Related Group (DRG) national tariffs). We estimated costs per different patient groups: non-asthma controls, mild/moderate and severe asthmatics. Final results report estimated direct cost per patient and total direct cost for overall target population, showing economic impact related to corticosteroid complication.
Results
Based on epidemiological data input, in Italy, asthmatic subjects resulted about 3,999,600, of which 199,980 with severe asthma. The number of patients with severe asthma OCS-treated was estimated at 123,988. Compared to the non-asthma control cohort and to that with moderate asthma annual cost per severe asthmatic patient resulted respectively about €892 and €606 higher, showing a corticosteroids shadow cost ranging from 45% to 30%.
Applying the cost per patient to the target population identified for Italy, the budget impact model estimated a total annual cost related to OCS-related adverse events of €242.7 million for severe asthmatics. In respect with non-asthmatic and moderate population, an incremental expenditure of about € 110.6 million and €75.2, respectively, were shown.
Conclusions
Our study provides the first estimates of additional healthcare costs related to corticosteroid induced adverse events in severe asthma patient. Budget impact model results highlighted the relevant economic impact of OCS-related adverse events in severe asthma patients. The future extrapolation of additional data from SANI registry will support the development of a model to investigate the role of corticosteroids sparing drugs.
Keywords
Severe asthma
Oral corticosteroids
Adverse events
Pharmacoeconomy
Costs
Diabetes
Glaucoma
Obesity
Bone fracture
Chronic kidney disease
KBJ00000000012683
2020-04-22T18:49:28
S300.3
S300
S1939-4551(19)30052-3
10.1016/j.waojou.2018.12.001
WAOJOU
1939-4551
7
100007
FLA
NON-CRC
UNLIMITED
NONE
2019-01-26T01:17:26Z
19394551/v12i1/S1939455119300523/main.xml
120132
MAIN
JA 5.5.0 ARTICLE
FULL-TEXT
19394551/v12i1/S1939455119300523/main.assets/gr3.jpg
14798
IMAGE-DOWNSAMPLED
19394551/v12i1/S1939455119300523/main.assets/gr1.jpg
13629
IMAGE-DOWNSAMPLED
19394551/v12i1/S1939455119300523/main.assets/gr2.jpg
14225
IMAGE-DOWNSAMPLED
19394551/v12i1/S1939455119300523/main.assets/gr3.sml
4679
IMAGE-THUMBNAIL
19394551/v12i1/S1939455119300523/main.assets/gr1.sml
4904
IMAGE-THUMBNAIL
19394551/v12i1/S1939455119300523/main.assets/gr2.sml
3455
IMAGE-THUMBNAIL
19394551/v12i1/S1939455119300523/main.pdf
546734
MAIN
1.7 6.5
DISTILLED OPTIMIZED BOOKMARKED
19394551/v12i1/S1939455119300523/main.raw
46019
S1939-4551(19)X0002-2
WAOJOU
1939-4551
12
1
2019
S1939-4551(19)30052-3
10.1016/j.waojou.2018.12.001
100007
main.pdf
PDF
1.7
local
1587981042176
collectiebehoudsniveau 1
2020-04-27T10:37:17.334+02:00
local
1587981042688
0
SHA-512
b565273d1e6d445c2f535aecd13c2d403deab69fcfd3565226da6bc3d492399649c3a0ecaebac4e76b78d087a81f6dd7e952dc990e05380b25d5d89cae3fb621
java.security.MessageDigest
546734
Adobe Acrobat Document
1.7
DIAS
62
DIAS tentative identification
main.pdf
local
1587981042689
0
SHA-512
41eeba65b640060e037834110f045542ad56a2ea032bd78ac18d3b1031630f4083db38855ce78ca484fb09d32530daecbd6e6489795c82dfc2cdb80c4b3529b3
java.security.MessageDigest
46019
not checked
main.raw
local
1587981042690
0
SHA-512
fe9c4120175ef800352bf21e60ffeda59e67d08dc0d560a39574243c9e426a6ba17512ee2cdeaf1e5e2ca88795aaabb9599880c8fb2b0eeff6b421580827b91a
java.security.MessageDigest
120132
not checked
main.xml
local
1587981042691
0
SHA-512
615a3a02e633f6021dd6e60d1cbe56bfc662bcfd3f07a95ae22bd683e56ec01796655cdd6f0258abba57c7c433b6ac50bf65119cdd22688f96b22d823093a21f
java.security.MessageDigest
13629
not checked
gr1.jpg
local
1587981042692
0
SHA-512
c72ce922ecd1c2b1d3a57c1fc362511758f83f956f22081f51bbb322dd59903f933e4728a1c64155a223c988139837badf2eb22db6d4c42abda502a18fb8baad
java.security.MessageDigest
4904
not checked
gr1.sml
local
1587981042693
0
SHA-512
c392351605765caef8163b516d1e0d269df7f3c6940ebdf530caa756c4cf76cc5fbe5ab5973d79dd240a94a45e237138fe0e8809a90d83dad1e91aa1d57d6653
java.security.MessageDigest
14225
not checked
gr2.jpg
local
1587981042694
0
SHA-512
a9c4e9a873c95e33f2fa9c72d49fd0be657585347c40cf93e175aab98a00c593dff284728d2bb8b0c4bcde02666a7edea897c66deaed15be4869ea0fb9045985
java.security.MessageDigest
3455
not checked
gr2.sml
local
1587981042695
0
SHA-512
327319d954fd9e760852a41c37fdb9bad624424b2bbadf1fe49a4d4abf1112ecc85774cb762a19a7dcb36e3b00b6f2e0b3682239e5e8a14d3411231560769d40
java.security.MessageDigest
14798
not checked
gr3.jpg
local
1587981042696
0
SHA-512
2ab1a6a02e335e3c8e5d26d766c455f56bf7f48d0261fdb197c4c9029108441186ae80e5a0c39d8118f02c205eaa2ce6665ff890d4d89984435d562d4348be06
java.security.MessageDigest
4679
not checked
gr3.sml
local
1587981042697
0
SHA-512
9798a909e44bbb2bfe9f1ba3ac7595fb7b52fdb57b0db42a1b19c32887556946d19454124684643c61ef97cebd3da917fc2f2da6c5bc05974061179092d238cb
java.security.MessageDigest
32445
not checked
metadata.xml
free
00001
The Authors
KB-agent-id
1
supplier
KB-owner-id
00001
KB-agent-id
1
Elsevier
organization
The Authors
ingestion
2020-04-27T10:37:17.334+02:00
Connector
software
Digitaal Magazijn release 1.5
ejournals_esp_1
streamprofile
ingestion2020-04-27T12:09:03.254+01:00Generic IngestsoftwareDigitaal Magazijn release 1.5